University of Gondar
58
54
The University of Gondar is working with IDDO to develop VL data standards.
University of Gondar - Gondar, Ethiopia
Research theme
CDISC
18
42
IDDO is working with CDISC to develop VL data standards.
CDISC - Austin, Texas
Research theme
PATH
69
43
IDDO is working with PATH to develop VL data standards. PATH has also contributed data to the VL data platform.
PATH, New Delhi (India office)
Research theme
Centro de Inteligência em Agravos Tropicais Emergentes a Negligenciadas (CIATEN)
34
64
CIATEN are represented on the VL Scientific Advisory Committee
Centro de Inteligência em Agravos Tropicais Emergentes a Negligenciadas (CIATEN), Brazil
Research theme
Kala - Azar Medical Research Centre
71
45
IDDO is working in partnership with the Kala – Azar Medical Research Centre, SitaRam Memorial Trust, on data contribution, training and the development of VL data standards.
Kala – Azar Medical Research Centre - Bihar, India
Research theme
Global call for strategic planning for COVID-19 medical products
09 Apr 2020
Global health experts have united in a call for governments and international organisations around the world to plan strategically for the coordinated production, equitable distribution and surveillance of COVID-19 medical products to ensure access to quality-assured medications for everyone.
The comment piece, published in The Lancet Global Health, was signed by 55 signatories from across 20 countries.
Enormous emergency efforts are underway to find optimal medical products, to prevent, diagnose, and treat COVID-19, which approximately 7.8 billion people will depend on. With significant disruption of pharmaceutical production and supply, and increasing numbers of falsified and substandard products, strategic planning is needed now to ensure global access to quality-assured medical products and monitoring of supply chains.
Co-author Professor Paul Newton, who leads Medicine Quality at IDDO, said: ‘‘Vital interventions are needed to ensure global manufacture, access, protection, and monitoring of supply chains.
“The emergence of COVID-19 risks a parallel pandemic of substandard and falsified products unless we all act to ensure that there is a global plan for coordinated production and surveillance of the quality of the tests, medicines and vaccines that the world’s 7.8 billion people will depend on.
“There are multiple priorities in tackling this severe emergency but in the face of the unescapable shortages, disruption of supply chains and national hoarding, advance planning for ensuring access to good quality medical products, both for the multitude of diseases humans suffer from and for COVID-19 is vital – otherwise the benefits of modern medicine will be negated and people will die younger than they would have done without COVID-19.
“All our fates are bound together and any helpful COVID-19 products must be recognised as global assets.”
Read the full article here.
MSF
49
33
Médecins Sans Frontières (MSF) has contributed data to the VL data platform, has a member on the VL Scientific Advisory Committee and is working with IDDO to develop VL data standards.
Médecins Sans Frontières, Geneva
Research theme
Institute of Tropical Medicine
48
31
The Institute of Tropical Medicine has contributed data to the VL data platform and has membership on the VL Scientific Advisory Committee.
Institute of Tropical Medicine, Antwerp
Research theme
DNDi
48
33
IDDO's work with the Drugs for Neglected Diseases Initiative (DNDi) aims to accelerate the drug discovery pathway by ensuring that all future scientific work across VL is founded on the most complete aggregation of the existing evidence.
DNDi, Geneva
Research theme
Category
Rupert
Higgins
Data Manager
Email
Research Theme
Ebola
Schistosomiasis & STHs
Malaria
Chagas
Visceral leishmaniasis
COVID19
WWARN
As a Data Manager at IDDO, Rupert is responsible for the management and transformation of diverse data sets for the organization. Rupert ensures the completeness and accuracy of the data in the IDDO repository, with a focus on malaria and Covid-19 research themes.
Rupert brings a diverse background to the role, having previously worked in the administration of clinical trials at the Ageing and Epidemiology Research Group and as a Sample Manager at the Forensic Toxicology Unit both at Imperial College London.
Prior to these roles, Rupert spent three years as a Quality Analyst in the pharmaceutical industry.
Rupert holds a degree in Biology with Psychology from Queen Mary University of London.